Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways - PubMed (original) (raw)
Review
. 2005 Oct 15:14 Spec No. 2:R251-8.
doi: 10.1093/hmg/ddi260.
Affiliations
- PMID: 16244323
- DOI: 10.1093/hmg/ddi260
Review
Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways
David J Kwiatkowski et al. Hum Mol Genet. 2005.
Abstract
Tuberous sclerosis complex (TSC) is an autosomal dominant disorder that is characterized by benign tumors (hamartomas and hamartias) involving multiple organ systems, due to inactivating mutations in TSC1 or TSC2. Here, we review recent advances in our understanding of the growth and signaling functions of the TSC1 and TSC2 proteins. Led by seminal studies in Drosophila, the TSC1/TSC2 complex has been positioned in an ancestrally conserved signaling pathway that regulates cell growth. TSC1/TSC2 receives inputs from at least three major signaling pathways in the form of kinase-mediated phosphorylation events that regulate its function as a GTPase activating protein (GAP): the PI3K-Akt pathway, the ERK1/2-RSK1 pathway and the LKB1-AMPK pathway. TSC1/TSC2 functions as a GAP towards Rheb, which is a major regulator of the mammalian target of rapamycin (mTOR). In the absence of either TSC1 or TSC2, high levels of Rheb-GTP lead to constitutive activation of mTOR-raptor signaling, thereby leading to enhanced and deregulated protein synthesis and cell growth. As a specific inhibitor of mTOR, rapamycin has therapeutic potential for the treatment of TSC hamartomas.
Similar articles
- Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease.
Astrinidis A, Henske EP. Astrinidis A, et al. Oncogene. 2005 Nov 14;24(50):7475-81. doi: 10.1038/sj.onc.1209090. Oncogene. 2005. PMID: 16288294 Review. - The mTOR/S6K signalling pathway: the role of the TSC1/2 tumour suppressor complex and the proto-oncogene Rheb.
Nobukini T, Thomas G. Nobukini T, et al. Novartis Found Symp. 2004;262:148-54; discussion 154-9, 265-8. Novartis Found Symp. 2004. PMID: 15562827 Review. - Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models.
Lee L, Sudentas P, Donohue B, Asrican K, Worku A, Walker V, Sun Y, Schmidt K, Albert MS, El-Hashemite N, Lader AS, Onda H, Zhang H, Kwiatkowski DJ, Dabora SL. Lee L, et al. Genes Chromosomes Cancer. 2005 Mar;42(3):213-27. doi: 10.1002/gcc.20118. Genes Chromosomes Cancer. 2005. PMID: 15578690 - Insulin and amino-acid regulation of mTOR signaling and kinase activity through the Rheb GTPase.
Avruch J, Hara K, Lin Y, Liu M, Long X, Ortiz-Vega S, Yonezawa K. Avruch J, et al. Oncogene. 2006 Oct 16;25(48):6361-72. doi: 10.1038/sj.onc.1209882. Oncogene. 2006. PMID: 17041622 Review. - Measurements of TSC2 GAP activity toward Rheb.
Li Y, Inoki K, Vikis H, Guan KL. Li Y, et al. Methods Enzymol. 2006;407:46-54. doi: 10.1016/S0076-6879(05)07005-9. Methods Enzymol. 2006. PMID: 16757313
Cited by
- mTORC1 hampers Hedgehog signaling in Tsc2 deficient cells.
Larsen LJ, Østergaard E, Møller LB. Larsen LJ, et al. Life Sci Alliance. 2024 Aug 26;7(11):e202302419. doi: 10.26508/lsa.202302419. Print 2024 Nov. Life Sci Alliance. 2024. PMID: 39187374 Free PMC article. - Carbonic Anhydrase 2 Deletion Delays the Growth of Kidney Cysts Whereas Foxi1 Deletion Completely Abrogates Cystogenesis in TSC.
Barone S, Zahedi K, Brooks M, Soleimani M. Barone S, et al. Int J Mol Sci. 2024 Apr 27;25(9):4772. doi: 10.3390/ijms25094772. Int J Mol Sci. 2024. PMID: 38731991 Free PMC article. - Early Post-Natal Immune Activation Leads to Object Memory Deficits in Female Tsc2+/- Mice: The Importance of Including Both Sexes in Neuroscience Research.
López-Aranda MF, Bach K, Bui R, Phan M, Lu O, Thadani C, Luchetti A, Mandanas R, Herrera I, López-Ávalos MD, Silva AJ. López-Aranda MF, et al. Biomedicines. 2024 Jan 17;12(1):203. doi: 10.3390/biomedicines12010203. Biomedicines. 2024. PMID: 38255309 Free PMC article. - Not all kidney cysts are created equal: a distinct renal cystogenic mechanism in tuberous sclerosis complex (TSC).
Soleimani M. Soleimani M. Front Physiol. 2023 Nov 8;14:1289388. doi: 10.3389/fphys.2023.1289388. eCollection 2023. Front Physiol. 2023. PMID: 38028758 Free PMC article. Review. - Early Treatment with Vigabatrin Does Not Decrease Focal Seizures or Improve Cognition in Tuberous Sclerosis Complex: The PREVeNT Trial.
Bebin EM, Peters JM, Porter BE, McPherson TO, O'Kelley S, Sahin M, Taub KS, Rajaraman R, Randle SC, McClintock WM, Koenig MK, Frost MD, Northrup HA, Werner K, Nolan DA, Wong M, Krefting JL, Biasini F, Peri K, Cutter G, Krueger DA; PREVeNT Study Group. Bebin EM, et al. Ann Neurol. 2023 Aug 28:10.1002/ana.26778. doi: 10.1002/ana.26778. Online ahead of print. Ann Neurol. 2023. PMID: 37638552
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous